Pharmaceuticals Trio Draw Buy Ratings Ahead of 2026 Catalysts
A trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A quick evaluation of altcoin teams in 2024, focusing on development cadence, leadership experience, and past deliverables.
27,759 articlesA trio of small-cap biotechs—X4 Pharmaceuticals, Immuneering, and Tango Therapeutics—are attracting new and renewed a...
A new wave of tech IPOs is poised to influence index funds and passive strategies. Learn what it means for your portf...
T-Mobile US leads on postpaid customer growth and cash flow, while Vodafone accelerates cross-border restructuring an...
Bitcoin remains in a delicate balance, trading around the $62,000s as traders watch a stubborn $63,000 barrier. Analy...
Poland has reached a trillion-dollar economy milestone in 2025, lifting tens of millions into a higher standard of li...
XRP remains in a tight battle between support and supply as July markets unfold. A breach of key levels could set XR...
A new income-focused ETF blend aims to provide steady monthly cash flow even as markets swing. By splitting $100,000 ...
The SEC and CFTC jointly designate XRP as a digital commodity alongside Bitcoin and Ethereum, removing its security l...
Fluence Energy surged nearly 100% in a week on big contract wins and a growing backlog. A quartet of AI-exposed energ...
Wingstop has slumped 60% in the last year amid a negative equity balance sheet. Meanwhile, three asset-heavy stocks—r...
A New York rally billed as a discussion on the economy devolved into tangents about toiletries and voter rules, under...
A 67-year-old retiree pursues $1,950 monthly from a $325,000 pool, using a disciplined four-fund approach to target a...